INITIATOR
Financiado
CIRCULATING TUMOR DNA AS AN EPIGENETIC BIOMARKER FOR TUMOR RESPONSE
Tumors are characterized by a disorganized vasculature, leading to profound levels of hypoxia. Normalizing the blood vessel formation (angiogenesis) in tumors has therefore become an attractive therapeutic strategy, leading to the...
Tumors are characterized by a disorganized vasculature, leading to profound levels of hypoxia. Normalizing the blood vessel formation (angiogenesis) in tumors has therefore become an attractive therapeutic strategy, leading to the development of approved drugs that inhibit major angiogenic pathways. Resistance however restricts the success of these anti-angiogenic drugs in some patients. There is thus a great clinical need for readily accessible markers that serve as reliably predictive biomarkers of anti-angiogenic therapies. However, all markers discovered to date have a limited predictive power. In the ERC Consolidator Grant CHAMELEON, we discovered how tumor hypoxia causes DNA hypermethylation and how changes in DNA methylation underlie resistance to anti-angiogenesis. Here, we propose to validate how methylation patterns detectable in plasma circulating free DNA from a prospective collection of patients with metastatic colorectal cancer can be used to predict an early response to anti-angiogenic therapies by using our in-house developed cfDNA co-methylation test, referred as the ‘INITIATOR’ test. If successful, we anticipate that this project will overcome many of the issues that are currently associated with anti-angiogenic drugs: cfDNA is readily accessible and can be serially sampled during treatment or follow-up, cfDNA also mirrors the entire tumor and not just the biopsied site, while the epigenetic changes detectable in cfDNA may be a dynamic representation of the tumor in response to treatment.
ver más
Duración del proyecto: 21 meses
Fecha Inicio: 2020-04-29
Fecha Fin: 2022-01-31
Fecha Fin: 2022-01-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-01-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2019-POC:
ERC Proof of Concept Grant
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
VIB VZW
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
720.30K€ |
Participante